Blog

Durvalumab and chemotherapy improves survival in MIBC – Uro Today

urotoday.com

Dec 17, 2024, 23:36

Durvalumab and chemotherapy improves survival in MIBC – Uro Today

“NIAGARA trial shows durvalumab + chemotherapy improves survival in MIBC.

Tom Powles, Barts Cancer Institute (Queen Mary) and Zach Klaassen discuss the NIAGARA trial results which examined the addition of durvalumab to cisplatin-based chemotherapy in the perioperative setting for muscle-invasive bladder cancer, representing the largest trial in this space with 1,000 patients.

Full Video on UroToday.

Barts Cancer Institute bladder cancer cancer chemotherapy Durvalumab fight against cancer Global fight against cancer MIBC NIAGARA OncoDaily Oncology Queen Mary Tom Powles UroToday UroToday.com Zach Klaassen

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Special Coverage